The malignancy, arising after the long carrier phase, may be manifested as a lymphoma or acute leukemia, with high white blood cell count and a poor prognosis, usually being fatal within 6–8 months. Smoldering and chronic forms of ATL can convert into an acute course. Approximately 3% of ...
成人T细胞白血病/淋巴瘤(adultT-cell leukemia/lymphoma, ATL)是一种高度侵袭性的T细胞恶性肿瘤,发生于部分长期携带1型人类T淋巴细胞病毒的携带者中。侵袭性亚型的中位生存期为8个月-10个月;采用基于化疗的治疗方法,自ATL首次被描述以来,总生存期在35年内基本保...
T cell acute lymphoblastic leukemia (T-ALL) is difficult to treat when it relapses after therapy or is chemoresistant; the prognosis of patients with relapsed or refractory T-ALL is generally poor. We report a case series of 17 such patients who received autologous chimeric antigen receptor (C...
A) The column graph shows the number of patients with different survival states. CR: complete response; PD: progressive disease. (B, C) The Kaplan-Meier survival curves show the progression-free survival (PFS) rate (B) and the overall survival (OS) rate (C) of all 74 patients at a ...
peptides from the intracellular lymphoid-specific enzyme terminal deoxynucleotidyl transferase (TdT), presented in the context of HLA-A*02:01, specifically eliminate primary acute lymphoblastic leukemia (ALL) cells of T- and B-cell origin in vitro and in three mouse models of disseminated B-ALL....
SURVIVAL ratePATIENTS' attitudesLYMPHOMASBackground and Objectives: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive T-cell lymphoproliferative disease associated with the human T-cell lymphotropic virus type I (HTLV-1). ATLL is a rare disease, found more freq...
It has been nearly half a century since angioimmunoblastic T-cell lymphoma (AITL) was characterized in the early 1970’s. Our understanding of the disease has dramatically changed due to multiple discoveries and insights. One of the key features of AITL
Extranodal natural killer (NK)/T-cell lymphoma (ENKTCL), nasal type is a rare and highly aggressive disease with distinct clinicopathological features. While the majority of patients with ENKTCL have localized disease within the nasal cavity, the overall prognosis is poor and it is often difficult...
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy arising from aberrant proliferation of immature T cell progenitors and accounts for about 15% of pediatric ALL cases1. The current risk-adapted, multiagent chemotherapeutic regimen has led to an overall survival rate exceeding ...
Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(−) disease. We report that CD19(−) escape is ass